Octocog alfa, plasma/albumin-free method

Drugs

Volumn 65, Issue 18, 2005, Pages 2613-2620

  McCormack, Paul L ^a   Plosker, Greg L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; RECOMBINANT BLOOD CLOTTING FACTOR 8;

AREA UNDER THE CURVE; BLEEDING; CLINICAL TRIAL; COST OF ILLNESS; DIZZINESS; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MARKETING; DRUG MECHANISM; DRUG STABILITY; DRUG TOLERABILITY; FEVER; FLUSHING; HEADACHE; HEMATOMA; HEMOPHILIA A; HOSPITAL COST; HUMAN; NONHUMAN; PLASMA; REVIEW; SIDE EFFECT; SKIN REDNESS; TEMPERATURE DEPENDENCE;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS; FACTOR VIII; HUMANS; MIDDLE AGED; RECOMBINANT PROTEINS;

ANIMALIA;

EID: 30044450968     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200565180-00005     Document Type: Review

References (21)

1. Mannucci PM, Tuddenham EGD. The hemophilias: from royal genes to gene therapy. N Engl J Med 2001 Jun 7; 344: 1773-9
2. Santagostino E, Gringeri A, Mannucci PM. State of care for hemophilia in pediatric patients. Pediatric Drugs 2002; 4 (3): 149-57
3. Baxter Healthcare Corporation. ADVATE Octocog alfa (recom-binant coagulation factor VIII): product monograph. 2004 Sep
4. Bjorkman S, Berntorp E. Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. Clin Pharmacokinet 2001; 40 (11): 815-32
5. National Hemophilia Foundation. MASAC recommendations concerning the treatment of hemophilia and other bleeding disorders. MASAC Document #151 [online]. Available from URL: http://www.hemophilia.org/research/masac/ masac151.pdf [Accessed 2005 Sep 10]
6. United Kingdom Haemophilia Centre Doctor's Organisation. Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. Haemophilia 2003 Jan; 9 (1): 1-23
7. ADVATE (octocog alfa): summary of product characteristics [online]. Available from URL: http://www.emea.eu.int/human docs/Humans/EPAR/advate/advate. htm [Accessed 2005 Sep 27]
8. Baxter Healthcare SA. Baxter announces European Union ex-panded approval of ADVATE for use in children with haemophilia A less than six years old [media release; online]. 2004 Dec 23. Available from URL: http://www.baxter.com [Accessed 2005 Nov 25]
9. European Medicines Agency. Advate. European public assess-ment report: scientific discussion [online]. Available from URL: http://www.emea.eu.int/ humandocs/Humans/EPAR/advate/ advate.htm [Accessed 2005 Sep 10]
10. Ewenstein BM, Collins P, Tarantino MD, et al. Hemophilia therapy innovation: development of an advanced category recombinant factor VIII by a plasma/albumin-free method. Proceedings of a Special Symposium at the XIXth Congress of the International Society on Thrombosis and Haemostasis, July 12-18, 2003, Birmingham, UK. Semin Hematol 2004 Apr; 41 (2 Suppl. 2): 1-16; discussion 16-18
11. Parti R, Schoppmann A, Lee H, et al. Stability of lyophilized and reconstituted plasma/albumin-free recombinant human factor VIII (ADVATE rAHF-PFM). Haemophilia 2005; 11: 492-6
12. Tarantino MD, Collins PW, Hay CR, et al. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. Haemophilia 2004 Sep; 10 (5): 428-37
13. Liesner R, Shapiro A, Blanchette V, et al. Pharmacokinetics, safety and efficacy of ADVATE rAHF-PFM in previously treated patients less than 6 years old [poster]. 20th Congress of the International Society on Thrombosis and Haemostasis; 2005 Aug 6-12; Sydney
14. Négrier C, Shapiro A, Pabinger I, et al. Clinical efficacy and safety evaluation of ADVATE antihemophilic factor (recombinant), plasma/albumin-free method (rAHF-PFM) during sur-gical and invasive procedures [poster]. 20th Congress of the International Society on Thrombosis and Haemostasis; 2005 Aug 6-12; Sydney
15. Sclar DA, Evans MA, Skaer TL, et al. Economic and epidemiological modelling of full-length antihaemophilic factor (re-combinant), plasma/albumin-free method, in previously treat-ed patients with haemophilia A: comparison with B-domain deleted rFVIII, and value of potential viral transmission reduc-tion due to plasma/albumin-free status. Drugs RD 2005; 6 (3): 149-56
16. Gomperts ED, Ewenstein BM, O'Banion ME, et al. The grow ing body of evidence on safety profile of ADVATE antihemophilic factor (recombinant) plasma/albumin-free method (rAHF-PFM) [poster]. 2004 Annual Meeting of the American Society of Hematology; 2004 Dec 4-7; San Diego (CA)
17. Gomperts E. ADVATE inhibitor risk profile: 18 months post-licensure. In: Scharrer I, Schramm W, editors. 35th Hemophilia Symposium Hamburg 2004. Heidelberg: Springer-Verlag. In press
18. Ewenstein BM, Gomperts ED, Pearson S, et al. Inhibitor development in patients receiving recombinant factor VIII (Recom-binate rAHF/Bioclate): a prospective pharmacovigilance study. Haemophilia 2004 Sep; 10 (5): 491-8
19. Baxter Healthcare Corporation. ADVATE antihemophilic fac-tor (recombinant), plasma/albumin-free method (rAHF-PFM): US prescribing information [online]. Available from URL: http://www.advate.com [Accessed 2005 Oct 27]
20. Baxter Healthcare Corporation. FDA approves Baxter's AD-VATE for the treatment of hemophilia A [media release; online]. 2003 Jul 25. Available from URL: http://www. baxter.com [Accessed 2005 Nov 25]
21. Baxter Healthcare Pty Ltd. Baxter receives marketing approval from Australia's Therapeutic Goods Administration for AD-VATE to treat haemophilia A [media release; online]. 2005 Apr 14. Available from URL: http://www.baxter.com [Accessed 2005 Nov 25]